Skip to main content

Be ready for invasive fungal infections (IFIs)

Lady looking upwards happily

I Am… AmBisome®

In a changing landscape of fungal pathogens, AmBisome® is ready to help you take on invasive fungal infections (IFIs) with confidence.1-5

3D image of yellow liposome

STAY ONE STEP AHEAD OF IFIs WITH AMBISOME®

  • Broad-spectrum efficacy against a variety of fungal pathogens2-4,6
  • Fungicidal activity against most clinically important yeasts and moulds2,7
  • Lower toxicity vs. conventional amphotericin B formulations8-15
  • Lower risk of drug-drug interactions vs. azoles5,16-21
  • Improved tissue penetration vs. conventional amphotericin B22
  • Empiric indication5
  • Low risk of resistance6,23-26
  • Well established tolerability and safety profile*5
  • Over three decades of clinical experience27

I Am… effective against a broad spectrum of fungal pathogens2-4,6

AmBisome® has a broad spectrum of activity against most fungal pathogens, including those causing rare and difficult-to-treat infections.2-4,28

Additionally, AmBisome® demonstrates fungicidal activity against most clinically important yeasts and moulds, including:2,6,7

  • A multitude of Candida species, including both C. albicans and non-albicans species
  • Aspergillus fumigatus and Aspergillus flavus
  • Mucorales
  • Cryptococcus neoformans
  • Histoplasma capsulatum
Man wearing red shirt looking pensive

Treat promptly and broad with AmBisome®

Be ready for IFIs by choosing to treat promptly with AmBisome®’s broad-spectrum activity.

I Am… established in a variety of at-risk patient populations

The efficacy of AmBisome® has been established in a variety of at-risk patient populations, including those with:

Haematological
disorders13,29-32
Stem cell transplantations
(allogenic/autologous)29
Solid organ
transplants29,30
Post-viral
infections33,34
HIV/AIDS29,35-38
Neutropenia13,29,31,32
Diabetes mellitus30
Critical conditions in the ICU29
Pancreatitis30
Sepsis or septic shock39
Image of nurse changing IV bag

I Am… associated with a lower risk of drug-drug interactions vs. azoles5,18-21,40

Fewer clinically relevant drug-drug interactions (DDIs) have been reported with AmBisome® vs. azoles.5,18-21,40 Azoles are contraindicated or require dose adjustments in patients treated with drugs that are frequently used in patients at high risk of IFIs.18-21,40

Close-up of doctor’s and patient’s hands

For patients on multiple medications, consider a treatment with fewer DDIs vs. azoles5,18-21,40

Learn more about the interactions of AmBisome® and azoles with other treatments commonly used in patients most at risk of developing an IFI.

I Am… the liposomal form of amphotericin B that sets me apart from other conventional forms of amphotericin B8,9,41

The liposomal delivery of AmBisome® reduces toxicity vs. other forms of amphotericin B, whilst retaining antifungal action.5,8-15 AmBisome® has a targeted liposomal delivery system (a liposome bilayer) that encapsulates amphotericin B, minimising adverse effects on host tissues and significantly reducing frequency of infusion-related reactions (P<0.001), nephrotoxic effects (P<0.001) and hypokalaemia (P=0.02) in febrile neutropenic patients vs. conventional amphotericin B.*8,12,13,42

AmBisome® also demonstrates improved tissue penetration with sustained drug levels and activity in key target tissues including the brain, lungs, kidneys, liver, and spleen vs. conventional amphotericin B.22

See how AmBisome®'s mechanism of action can help to reduce toxicity compared with conventional amphotericin B.

Image of vials with yellow fluid

Choose a treatment that has a well established tolerability and safety profile*5

Discover in more detail how AmBisome®’s liposomal delivery reduces nephrotoxicity vs. conventional amphotericin B and find out about adverse events associated with AmBisome®

Microscopic photo of Aspergillus on blue background

I Am… associated with low resistance6,23-26

After more than 50 years of clinical use, acquired resistance to amphotericin B, the active ingredient in AmBisome®, has rarely been reported.6,23-26

Microscopic photo of blue stained fungal pathogens

Take action in the face of growing resistance

Discover how AmBisome® can help you stay one step ahead of IFIs in a changing IFI landscape.

I Am… indicated in a broad range of iFIs5

AmBisome® is indicated in adults and children aged 1 month to 18 years old for:5

  • The treatment of severe systemic and/or deep mycoses
  • The treatment of visceral leishmaniasis in immunocompetent patients including both adults and children
  • The empirical treatment of presumed fungal infections in febrile neutropenic patients, where the fever has failed to respond to broad-spectrum antibiotics and appropriate investigations have failed to define a bacterial or viral cause

Infections successfully treated with AmBisome® include: disseminated candidiasis, aspergillosis, mucormycosis, chronic mycetoma, cryptococcal meningitis and visceral leishmaniasis.5

AmBisome® should not be used to treat the common clinically inapparent forms of fungal disease which show only positive skin or serologic tests.5

Close-up of doctor’s and patient’s hands

Treat promptly to improve the chance of survival in your patients46,47

When indicated, empirical treatment with a broad-spectrum, fungicidal treatment, even in the absence of a confirmed diagnosis, may help to reduce mortality.46-51

I AM... HELPING YOU TAKE ON IFIs WITH CONFIDENCE5

The dose of AmBisome® must be adjusted to the specific requirements of each patient. For more information on starting doses and escalation recommendations, please refer to the Summary of Product Characteristics.5

No adjustments in dose or frequency are required with AmBisome® in:5

  • Elderly patients
  • Patients with hepatic disorders
  • Paediatric patients
  • Patients with renal impairment§

I Am… AmBisome®, ready to help you fight the next suspected IFI5

Footnotes

*Double-blind, randomised trial comparing AmBisome® (initial dose of 3 mg/kg/day) and cAMB (0.6 mg/kg/day) as empiric antifungal therapy in adults and children (2-80 years) with persistent neutropenia (< 500/mm3) and fever despite >5 days empirical antibacterial therapy. The total number of patients was 687, of whom almost half (n=333) had acute leukemia. Treatment success (primary efficacy endpoint), was defined as a composite of five criteria: survival for seven days after initiation of the study drug; resolution of fever during the period of neutropenia; successful treatment of any base-line fungal infection, if present; the absence of breakthrough fungal infections during administration of the study drug or within seven days after the completion of treatment; and the absence of premature discontinuation of the study drug because of toxicity or lack of efficacy.13

2012 study conducted in 9,252 clinical isolates of Candida albicans.45

No data are available on which to make a dose recommendation for patients with hepatic impairment.

AmBisome® is not recommended for use in children below 1 month old due to lack of data on safety and efficacy.5

§AmBisome® has been administered to a large number of patients with pre-existing renal impairment at starting doses ranging from 1-3 mg/kg/day in clinical trials and no adjustment in dose or frequency of administration was required. AmBisome® has been shown to be substantially less toxic than conventional amphotericin B, particularly with respect to nephrotoxicity, however, renal adverse events may still occur. In particular, caution should be exercised when prolonged therapy is required. Regular laboratory evaluation of serum electrolytes, particularly potassium and magnesium, as well as renal, hepatic and haematopoietic function should be performed, at least once weekly. If clinically significant reduction in renal functioning, or worsening of other parameters occurs, consideration should be given to dose reduction, treatment interruption or discontinuation.5

References

  • Lamoth F et al. Clin Infect Dis. 2017;64(11):1619-1621.
  • Lass-Flörl C et al. Antimicrob Agents Chemother. 2008;52(10):3637-3641.
  • Almyroudis NG et al. Antimicrob Agents Chemother. 2007;51(7):2587-2590.
  • Chandrasekar P. J Antimicrob Chemother. 2011;66:457-465.
  • AmBisome® Summary of Product Characteristics (UK).
  • Nett JE and Andes DR. Infect Dis Clin North Am. 2016;30:51-83.
  • Meletiadis J et al. Antimicrob Agents Chemother. 2007;51(9):3329-3337.
  • Adler-Moore J and Proffitt RT. J Antimicrob Chemother. 2002;49(Suppl.1):21-30.
  • Keady S and Panesae P. EJHP Practice. 2010;16(3):78-80.
  • Falci DR et al. Mycoses. 2015;58:104-112.
  • Stone NR et al. Drugs. 2016;76(4):485-500.
  • Adler-Moore JP et al. Med Mycol. 2016;54(3):223-231.
  • Walsh TJ et al. N Engl J Med. 1999;340:764-71.
  • Ullmann A et al. Clin Infect Dis. 2006;43:e29-38.
  • Wingard JR et al. Clin Infect Dis. 2000;31:1155-1163.
  • European Medicines Agency (EMA). Rydapt (Midostaurin) Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/rydapt-epar-product-information_en.pdf [Last accessed: June 2022].
  • European Medicines Agency (EMA). Xospata (Gilteritinib) Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/xospata-epar-product-information_en.pdf [Last accessed: June 2022].
  • Youngs J et al. J Fungi (Basel). 2020;6(4):385.
  • European Medicines Agency (EMA). Vfend (Voriconazole) Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/vfend#product-information-section [Last accessed: June 2022].
  • European Medicines Agency (EMA). Noxafil (Posaconazole) Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/noxafil#product-information-section [Last accessed: June 2022].
  • European Medicines Agency (EMA). Cresemba (Isavuconazole) Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/cresemba#product-information-section [Last accessed: June 2022].
  • Adler-Moore JP et al. Curr Opin Investig Drugs. 2003;4(2):179-185.
  • Messer SA et al. Diagnos Microbiol Infect Dis. 2020;97:115007.
  • Mesa-Arango AC et al. Front Microbiol. 2012;3:286.
  • Vallejo C et al. Rev Esp Quimioter. 2013;26(4):378-386.
  • Vincent BM et al. PLoS Biol. 2013;11(10):e1001692.
  • AmBisome® Summary of Product Characteristics (Ireland).
  • Manavathu EK et al. J Antimicrob Chemother. 2000;46:229-234.
  • Cornely OA et al. Clin Infect Dis. 2007;44(10):1289-1297.
  • Kuse E-R et al. Lancet. 2007;369(9572):1519-1527.
  • Walsh TJ et al. N Engl J Med. 2002;346(4):225-234.
  • Walsh TJ et al. N Engl J Med. 2004;351(14):1391-1402.
  • Rutsaert L et al. Ann. Intensive Care. 2020;10:71. https://doi.org/10.1186/s13613-020-00686-4.
  • Koehler P et al. Clin Microbiol Infect. 2019;25(12):1501-1509.
  • Hamill RJ et al. Clin Infect Dis. 2010;51(2):225-232.
  • Wheat LG et al. Antimicrob Agents Chemother. 2001;45(8):2354-2357.
  • Wheat J et al. Medicine (Baltimore). 2018;97(13):e0245.
  • Johnson PC et al. Ann Intern Med. 2002;137(2):105-109.
  • Álvarez-Lerma F et al. J Chemother. 2009;21(3):330-337.
  • Jenks JD, et al. Med Mycol. 2019;57(Suppl.2):S168-S178.
  • Walker L et al. MBio. 2018;9(1):e02383-17.
  • Laurent A et al. Burns Open. 2020;4:110-116.
  • Verweij PE. Drug Resist Updat. 2015;21-22:30-40.
  • Verweij PE et al. Clin Infect Dis. 2016;62(3):362-368.
  • Pfaller MA et al. J Clin Microbiol. 2012;50(6):2040-2046.
  • Pappas PG et al. Nat Rev Dis Primers. 2018;11;4:18026.
  • Morrell M et al. Antimic Ag Chem. 2005:49(9):3640-45.
  • Bassetti M et al. Crit Care. 2014;18(4):458.
  • ESICM/ESCMID task force on practical management of invasive candidiasis in critically ill patients. Martin‑Loeches et al. Intensive Care Med. 2019;45(6):789-805.
  • Tashiro M et al. J Infect Chemother. 2021;S1341-321X(21)00174-4.
  • Nivoix Y et al. Clin Infect Dis. 2008;47(9):1176-1184.

Date of preparation: June 2022. Job code: IHQ-AMB-0706.